Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411064 | 0.84 | PKM (0.50) | PDE10APKMSMN1; SMN2L3MBTL1CA1 | |
| SCHEMBL3790518 | 0.76 | KMT2A (0.52) | PDE10APKMSMN1; SMN2CA9MEN1 | |
| SCHEMBL4306010 | 0.76 | MEN1 (0.52) | PKMSMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL135305 | 0.74 | CA12 (0.66) | PKMSMN1; SMN2CA9MEN1KMT2A | |
| SCHEMBL30098360 | 0.74 | CA12 (0.66) | PKMSMN1; SMN2CA9MEN1KMT2A | |
| SCHEMBL14876148 | 0.71 | TDP1 (0.64) | PDE10ASMN1; SMN2TDP1CA1CA2 | |
| SCHEMBL4235928 | 0.71 | ALDH1A1 (0.60) | TDP1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4582152 | 0.70 | MEN1 (0.82) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL25359709 | 0.69 | MEN1 (0.65) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6564387 | 0.69 | RAB9A (0.67) | SMN1; SMN2TDP1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435048-B1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2435048-B1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-03 | — | — | EP | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2632461-A1 | ISOINDOLINONE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| WO-2012058133-A1 | ISOINDOLINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| WO-2010138585-A1 | PYRIMIDINONES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138585-A1 | PYRIMIDINONES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138577-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | PDE5A, PDE3A, PDE10A | PDE10A 3/4885PKM 648/4885SMN1; SMN2 2515/4885 |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | PDE12, PDE10A, PDE4A | PDE10A 2/4885PKM 1760/4885SMN1; SMN2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.